Shanghai Micurx Pharmaceutical Co., Ltd.

The company was founded in 2007. It is an innovative biomedical enterprise with global independent intellectual property rights and international competitiveness with the treatment of infectious diseases as the core. It is committed to discovering, developing and commercializing innovative drugs that do not meet clinical needs. Since its inception, the company has always been adhering to the concept of “seeking good results with good medicine”, focusing on the increasingly serious problem of bacterial drug resistance around the world, solving clinical problems and differentiated innovation as its core competitiveness. The goal is to become a respected innovative drug leader, providing patients with better differentiated treatment products. The company's main business is the development and commercialization of novel antimicrobials. The main products are MRX-1 contezolamide tablets, MRX-4, MRX-8, MRX-5, etc.